ClinicalTrials.gg
Not yet recruitingNCT05966701Updated Aug 1, 2023

The MAD Study of SSGJ-613 in Healthy Subjects

A Phase 1 interventional study of SSGJ-613 and Placebo in Arthritis, Gouty, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Arthritis, Gouty with a site in China — 5 open to participants now, 6 under way, none of them phase 3. Arthritis, Gouty · China.

Planned enrollment
9th of 10
36 · median 134
Started
2023
with 1 other
Phase 1
3 of 11
1 open now
Registered
3rd of 11
by date
Lead sponsor
2 of 11
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Among the 11 studies in Arthritis, Gouty with a site in China, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 1, and was the 3rd registered.

Arthritis, Gouty

47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.

Browse Arthritis, Gouty studies →

Open to participants now

5 of the 11 studies in Arthritis, Gouty with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Arthritis, Gouty studies recruiting now, 8 (80%) set no upper age limit and 1 (10%) stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Arthritis, Gouty with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of SSGJ-613 after multiple subcutaneous injections in healthy subjects.

Read the detailed description

The purposes of this study are to evaluate the safety and tolerability, PK characteristics and immunogenicity of SSGJ-613 after multiple subcutaneous injections in healthy subjects.

03

Conditions studied

  • Arthritis, Gouty

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese healthy participants, male or female, aged 18 to 45 (including both ends)
  2. The (BMI) is in the range of 19.0\~28.0 kg•m-2 (including both ends), and the weight of men is generally not less than 50kg, while the women is generally not less than 45kg
  3. Participants should fully understand the purpose, nature, methods and possible adverse reactions of the trial, volunteer to participate in the trial and sign the

Exclusion criteria

Exclusion Criteria:

  1. Those who are allergic to the study drug and any of its . Subjects who have a history of allergy to monoclonal antibodies
  2. Subjects who have or are currently suffering from any serious clinical diseases before screening,
  3. Abnormal vital signs or abnormal ECGor physical examination are
  4. Clinical laboratory examinations found to be abnormal and have clinical significance
  5. Positive for surface antigen (HBsAg), hepatitis B core antibody (HbcAb), anti- virus antibodies (HCV), or anti- (HIV)
  6. Alcoholics or frequent drinkers within 3 months before the trial, drinking more than 14 units per week (1 unit alcohol ≈360 mL beer or 45 mL spirits or 150 mL wine), or those who have a positive alcohol breath test (screening period or baseline period) or couldn't prohibit alcohol during the trial
  7. Drug abusers or those who have used soft drugs (such as marijuana) within 3 months or took hard drugs (such as cocaine, phencyclidine, etc.) within 1 year before the trial, or have positive drug abuse screening
  8. Has taken any prescription medicine, non-prescription medicine, Chinese patent medicine within 2 weeks before administration
  9. Has known or suspected pregnancy or lactation
  10. Subjects who are unsuited to the study for any reason, judged by the investigators
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    SSGJ-613

    SSGJ-613,SC

    Drug: SSGJ-613

  • Placebo comparator
    Placebo

    Placebo, SC

    Drug: Placebo

Interventions

  • SSGJ-613 subcutaneous injection.

  • DrugPlacebo

    Placebo subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs), measurement of vital signs,physical examination,electrocardiogram and laboratory tests at each visit.

    The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations,electrocardiogram,laboratory tests and, etc..

    Time frame: Up to Day 174

Secondary outcomes

  1. SSGJ-613 Concentration in Serum

    The concentration of SSGJ-613 in Serum.

    Time frame: Up to Day 174

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2023; primary completion for Mar 2024, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Aug 1, 2023
StartEst.
Aug 10, 2023
Primary completionEst.
Mar 10, 2024
CompletionEst.
Mar 10, 2024
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05966701
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 10, 2023 (estimated)
Primary completion
Mar 10, 2024 (estimated)
Completion
Mar 10, 2024 (estimated)
Last update
Aug 1, 2023

Study contacts

Qinghong Zhou, BS
Contact
zhouqinghong@3sbio.com
+86 18911301578
Qinghong Zhou, BS
study director · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Qian Chen, PhD
principal investigator · Shanghai Xuhui District Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SSGJ-613

Start the discussion